Share Price and Basic Stock Data
Last Updated: December 30, 2025, 8:48 pm
| PEG Ratio | 0.47 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fortis Malar Hospitals Ltd operates in the Hospitals & Medical Services industry, with a current market capitalization of ₹108 Cr and a share price of ₹57.6. The company’s revenue has experienced significant fluctuations over recent quarters. Sales reported for the quarter ending September 2022 stood at ₹23.29 Cr but declined to ₹17.76 Cr by June 2023, indicating a downward trend. In contrast, there was a slight recovery with sales of ₹18.15 Cr in September 2023. The financial year ending March 2023 recorded total sales of ₹85.95 Cr, a marginal decrease from ₹86.18 Cr in March 2022. The company’s operational challenges are evident, as it reported a trailing twelve months (TTM) revenue of only ₹0.05 Cr, suggesting severe operational disruptions. The declining sales trend raises concerns about the company’s market positioning and ability to generate consistent revenue, particularly in a highly competitive healthcare environment.
Profitability and Efficiency Metrics
Fortis Malar Hospitals Ltd has faced considerable profitability challenges, as highlighted by its operating profit margin (OPM), which stood at -1,266.67% for the quarter ending September 2025. The company’s net profit for the same quarter was reported at ₹0.01 Cr, reflecting a drastic decline from previous periods. The annual net profit for March 2023 was recorded at -₹15.48 Cr, a significant drop from -₹8.27 Cr in March 2022. The return on equity (ROE) is notably low at 0.56%, while the return on capital employed (ROCE) stands at 0.83%, both of which are below typical sector benchmarks. The interest coverage ratio (ICR) of 56.70x indicates that the company can comfortably cover its interest obligations, suggesting a degree of financial stability despite its operational shortcomings. Overall, the company’s profitability metrics reveal significant operational inefficiencies and challenges in achieving sustainable profit generation.
Balance Sheet Strength and Financial Ratios
Fortis Malar Hospitals Ltd presents a mixed balance sheet picture, with total assets reported at ₹36.83 Cr for the financial year ending March 2025. The company holds no borrowings, which positions it favorably in terms of debt management. Additionally, reserves have decreased to ₹11.45 Cr from ₹61.37 Cr in March 2022, indicating a weakening financial cushion. The current ratio stands at 5.15, significantly above the typical benchmark of 1.5 for the healthcare sector, suggesting that the company has ample liquidity to meet its short-term obligations. However, the price-to-book value (P/BV) ratio of 4.56x suggests that the stock may be overvalued relative to its book value, which is reported at ₹16.11 per share. The financial ratios indicate a firm that, while it has liquidity, struggles with profitability and overall financial stability, requiring strategic management to enhance its operational performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Fortis Malar Hospitals Ltd reveals a strong promoter presence, with promoters holding 62.71% of the shares as of December 2023. The public holds 37.21%, while Foreign Institutional Investors (FIIs) are not reported, and Domestic Institutional Investors (DIIs) hold a minimal 0.07%. The number of shareholders has increased from 8,772 in December 2022 to 27,644 by September 2025, indicating growing interest and potential confidence from retail investors. However, the low institutional participation may reflect caution among professional investors regarding the company’s operational challenges and profitability issues. The significant promoter stake provides some assurance of commitment to the company’s future, but the lack of diversification in shareholding could pose risks in governance and strategic decision-making, particularly when facing operational difficulties.
Outlook, Risks, and Final Insight
The outlook for Fortis Malar Hospitals Ltd hinges on its ability to stabilize revenues and improve operational efficiencies. The reported sales decline and significant net losses present considerable risks to its future viability. The company must address its profitability issues, as the negative operating margins and low return ratios suggest a need for strategic restructuring. On the positive side, the absence of debt provides a buffer against financial distress and the high liquidity ratio indicates that it can manage short-term obligations effectively. However, without a clear strategy to enhance operational performance and profitability, the company may struggle to regain investor confidence. Future scenarios could involve either a successful turnaround through operational improvements or continued financial struggles leading to further declines in market position and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.3 Cr. | 144 | 187/120 | 9.86 | 117 | 2.43 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 25.7 Cr. | 24.4 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 8.40 Cr. | 8.12 | 20.8/7.08 | 93.4 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 108 Cr. | 57.6 | 98.7/55.2 | 23.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.2 Cr. | 3.74 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,873.86 Cr | 684.98 | 92.11 | 93.18 | 0.33% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 23.29 | 21.90 | 20.66 | 17.76 | 18.15 | 17.58 | 5.52 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
| Expenses | 21.01 | 20.30 | 19.93 | 18.27 | 18.23 | 18.67 | 5.04 | 0.88 | 0.47 | 0.41 | 0.37 | 0.35 | 0.41 |
| Operating Profit | 2.28 | 1.60 | 0.73 | -0.51 | -0.08 | -1.09 | 0.48 | -0.88 | -0.47 | -0.41 | -0.37 | -0.33 | -0.38 |
| OPM % | 9.79% | 7.31% | 3.53% | -2.87% | -0.44% | -6.20% | 8.70% | -1,650.00% | -1,266.67% | ||||
| Other Income | 1.50 | 1.52 | 1.97 | 1.61 | 2.31 | 1.26 | 59.69 | 0.83 | 0.56 | 0.56 | 0.77 | 4.61 | 0.52 |
| Interest | 1.61 | 1.49 | 1.42 | 1.35 | 1.30 | 1.26 | 0.39 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 2.91 | 2.78 | 3.44 | 2.67 | 2.72 | 2.91 | 1.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.74 | -1.15 | -2.16 | -2.92 | -1.79 | -4.00 | 58.72 | -0.06 | 0.09 | 0.15 | 0.40 | 4.28 | 0.14 |
| Tax % | 491.89% | 0.00% | 223.15% | 0.00% | 0.00% | 0.25% | 7.95% | 0.00% | 0.00% | 93.33% | 10.00% | 3.04% | 92.86% |
| Net Profit | -4.38 | -1.15 | -6.99 | -2.93 | -1.79 | -4.00 | 54.05 | -0.06 | 0.09 | 0.01 | 0.36 | 4.15 | 0.01 |
| EPS in Rs | -2.34 | -0.61 | -3.73 | -1.56 | -0.96 | -2.13 | 28.84 | -0.03 | 0.05 | 0.01 | 0.19 | 2.21 | 0.01 |
Last Updated: December 26, 2025, 11:07 pm
Below is a detailed analysis of the quarterly data for Fortis Malar Hospitals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.03 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Jun 2025) to 0.03 Cr., marking an increase of 0.01 Cr..
- For Expenses, as of Sep 2025, the value is 0.41 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.35 Cr. (Jun 2025) to 0.41 Cr., marking an increase of 0.06 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.38 Cr.. The value appears to be declining and may need further review. It has decreased from -0.33 Cr. (Jun 2025) to -0.38 Cr., marking a decrease of 0.05 Cr..
- For OPM %, as of Sep 2025, the value is -1,266.67%. The value appears strong and on an upward trend. It has increased from -1,650.00% (Jun 2025) to -1,266.67%, marking an increase of 383.33%.
- For Other Income, as of Sep 2025, the value is 0.52 Cr.. The value appears to be declining and may need further review. It has decreased from 4.61 Cr. (Jun 2025) to 0.52 Cr., marking a decrease of 4.09 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.14 Cr.. The value appears to be declining and may need further review. It has decreased from 4.28 Cr. (Jun 2025) to 0.14 Cr., marking a decrease of 4.14 Cr..
- For Tax %, as of Sep 2025, the value is 92.86%. The value appears to be increasing, which may not be favorable. It has increased from 3.04% (Jun 2025) to 92.86%, marking an increase of 89.82%.
- For Net Profit, as of Sep 2025, the value is 0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 4.15 Cr. (Jun 2025) to 0.01 Cr., marking a decrease of 4.14 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.01. The value appears to be declining and may need further review. It has decreased from 2.21 (Jun 2025) to 0.01, marking a decrease of 2.20.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:43 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 108.38 | 117.93 | 129.61 | 140.56 | 149.19 | 144.59 | 111.87 | 69.24 | 86.18 | 85.95 | 59.01 | 0.00 | 0.05 |
| Expenses | 99.39 | 110.37 | 123.31 | 139.64 | 147.44 | 146.94 | 114.57 | 75.58 | 82.74 | 81.38 | 60.22 | 2.14 | 1.54 |
| Operating Profit | 8.99 | 7.56 | 6.30 | 0.92 | 1.75 | -2.35 | -2.70 | -6.34 | 3.44 | 4.57 | -1.21 | -2.14 | -1.49 |
| OPM % | 8.29% | 6.41% | 4.86% | 0.65% | 1.17% | -1.63% | -2.41% | -9.16% | 3.99% | 5.32% | -2.05% | -2,980.00% | |
| Other Income | 6.85 | 7.63 | 7.21 | 7.95 | 8.44 | 10.03 | 11.11 | 15.10 | 7.39 | 6.64 | 64.88 | 2.72 | 6.46 |
| Interest | 0.46 | 0.51 | 0.40 | 0.46 | 0.38 | 0.51 | 7.81 | 7.20 | 6.56 | 6.07 | 4.30 | 0.01 | 0.00 |
| Depreciation | 1.99 | 2.71 | 3.16 | 3.94 | 4.21 | 4.38 | 12.53 | 12.88 | 12.53 | 12.15 | 9.36 | 0.00 | 0.00 |
| Profit before tax | 13.39 | 11.97 | 9.95 | 4.47 | 5.60 | 2.79 | -11.93 | -11.32 | -8.26 | -7.01 | 50.01 | 0.57 | 4.97 |
| Tax % | 34.43% | 34.25% | 35.58% | 30.20% | 40.54% | 26.16% | -25.48% | -30.48% | 0.12% | 120.97% | 9.36% | 31.58% | |
| Net Profit | 8.78 | 7.86 | 6.42 | 3.11 | 3.32 | 2.06 | -8.89 | -7.87 | -8.27 | -15.48 | 45.32 | 0.39 | 4.53 |
| EPS in Rs | 4.72 | 4.23 | 3.45 | 1.67 | 1.78 | 1.10 | -4.74 | -4.20 | -4.41 | -8.26 | 24.18 | 0.21 | 2.42 |
| Dividend Payout % | 10.60% | 11.84% | 14.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 175.93% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -10.48% | -18.32% | -51.56% | 6.75% | -37.95% | -531.55% | 11.47% | -5.08% | -87.18% | 392.76% | -99.14% |
| Change in YoY Net Profit Growth (%) | 0.00% | -7.84% | -33.24% | 58.31% | -44.70% | -493.60% | 543.03% | -16.56% | -82.10% | 479.95% | -491.90% |
Fortis Malar Hospitals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -100% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -26% |
| 5 Years: | 15% |
| 3 Years: | 27% |
| TTM: | 190% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 7% |
| 3 Years: | 3% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | -11% |
| 3 Years: | -10% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:53 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18.61 | 18.61 | 18.62 | 18.68 | 18.70 | 18.76 | 18.76 | 18.76 | 18.76 | 18.76 | 18.76 | 18.76 | 18.76 |
| Reserves | 66.20 | 72.63 | 79.02 | 80.87 | 84.35 | 86.62 | 77.65 | 69.99 | 61.37 | 45.42 | 90.71 | 11.45 | 15.62 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 64.34 | 57.17 | 53.41 | 46.40 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 16.67 | 19.68 | 32.55 | 31.14 | 46.03 | 45.46 | 32.80 | 23.18 | 27.37 | 27.42 | 6.41 | 6.62 | 2.81 |
| Total Liabilities | 101.48 | 110.92 | 130.19 | 130.69 | 149.08 | 150.84 | 193.55 | 169.10 | 160.91 | 138.00 | 115.88 | 36.83 | 37.19 |
| Fixed Assets | 17.63 | 17.71 | 24.50 | 24.59 | 23.79 | 21.85 | 81.08 | 68.52 | 57.62 | 47.41 | 0.00 | 0.00 | 0.00 |
| CWIP | 0.64 | 0.64 | 0.36 | 0.61 | 0.72 | 0.73 | 0.09 | 0.36 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 83.21 | 92.57 | 105.33 | 105.49 | 124.57 | 128.26 | 112.38 | 100.22 | 103.23 | 90.59 | 115.88 | 36.83 | 37.19 |
| Total Assets | 101.48 | 110.92 | 130.19 | 130.69 | 149.08 | 150.84 | 193.55 | 169.10 | 160.91 | 138.00 | 115.88 | 36.83 | 37.19 |
Below is a detailed analysis of the balance sheet data for Fortis Malar Hospitals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 18.76 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.76 Cr..
- For Reserves, as of Sep 2025, the value is 15.62 Cr.. The value appears strong and on an upward trend. It has increased from 11.45 Cr. (Mar 2025) to 15.62 Cr., marking an increase of 4.17 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2.81 Cr.. The value appears to be improving (decreasing). It has decreased from 6.62 Cr. (Mar 2025) to 2.81 Cr., marking a decrease of 3.81 Cr..
- For Total Liabilities, as of Sep 2025, the value is 37.19 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 36.83 Cr. (Mar 2025) to 37.19 Cr., marking an increase of 0.36 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 37.19 Cr.. The value appears strong and on an upward trend. It has increased from 36.83 Cr. (Mar 2025) to 37.19 Cr., marking an increase of 0.36 Cr..
- For Total Assets, as of Sep 2025, the value is 37.19 Cr.. The value appears strong and on an upward trend. It has increased from 36.83 Cr. (Mar 2025) to 37.19 Cr., marking an increase of 0.36 Cr..
Notably, the Reserves (15.62 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 8.99 | 7.56 | 6.30 | 0.92 | 1.75 | -2.35 | -67.04 | -63.51 | -49.97 | -41.83 | -1.21 | -2.14 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 13.13 | 13.03 | 16.93 | 14.49 | 14.68 | 24.39 | 12.17 | 11.02 | 9.32 | 13.50 | 0.00 | |
| Inventory Days | 4.02 | 13.24 | 35.39 | 28.37 | 22.30 | 18.04 | 22.44 | 42.32 | 39.89 | 31.71 | 0.00 | |
| Days Payable | 153.41 | 169.39 | 286.36 | 173.78 | 277.45 | 257.22 | 323.72 | 373.05 | 428.91 | 584.69 | ||
| Cash Conversion Cycle | -136.26 | -143.11 | -234.05 | -130.92 | -240.47 | -214.79 | -289.11 | -319.72 | -379.70 | -539.47 | 0.00 | |
| Working Capital Days | 187.38 | 163.79 | 126.13 | 152.64 | 131.84 | 155.53 | -55.01 | 114.55 | 21.60 | 183.80 | -8.35 | |
| ROCE % | 17.17% | 14.19% | 11.83% | 5.02% | 5.90% | 3.24% | -3.04% | -7.15% | -1.25% | -0.77% | -3.29% | 0.83% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.21 | 24.18 | -8.26 | -4.41 | -4.20 |
| Diluted EPS (Rs.) | 0.21 | 24.18 | -8.26 | -4.41 | -4.20 |
| Cash EPS (Rs.) | 0.20 | 29.15 | -1.78 | 2.27 | 2.67 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 16.11 | 58.36 | 34.21 | 42.72 | 47.31 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 16.11 | 58.36 | 34.21 | 42.72 | 47.31 |
| Revenue From Operations / Share (Rs.) | 0.00 | 31.46 | 45.82 | 45.94 | 36.92 |
| PBDIT / Share (Rs.) | 0.30 | 3.06 | 5.98 | 5.77 | 1.02 |
| PBIT / Share (Rs.) | 0.30 | -1.93 | -0.49 | -0.90 | -5.84 |
| PBT / Share (Rs.) | 0.30 | 26.66 | -3.74 | -4.40 | -6.03 |
| Net Profit / Share (Rs.) | 0.20 | 24.16 | -8.25 | -4.41 | -4.20 |
| NP After MI And SOA / Share (Rs.) | 0.20 | 24.16 | -8.25 | -4.41 | -4.20 |
| PBDIT Margin (%) | 0.00 | 9.74 | 13.04 | 12.56 | 2.76 |
| PBIT Margin (%) | 0.00 | -6.12 | -1.09 | -1.97 | -15.82 |
| PBT Margin (%) | 0.00 | 84.74 | -8.15 | -9.58 | -16.33 |
| Net Profit Margin (%) | 0.00 | 76.81 | -18.01 | -9.60 | -11.36 |
| NP After MI And SOA Margin (%) | 0.00 | 76.81 | -18.01 | -9.60 | -11.36 |
| Return on Networth / Equity (%) | 1.29 | 41.40 | -24.12 | -10.32 | -8.86 |
| Return on Capital Employeed (%) | 1.91 | -3.29 | -0.88 | -1.31 | -7.59 |
| Return On Assets (%) | 1.06 | 39.11 | -11.21 | -5.14 | -4.65 |
| Asset Turnover Ratio (%) | 0.00 | 0.46 | 0.57 | 0.52 | 0.38 |
| Current Ratio (X) | 5.15 | 17.68 | 2.66 | 1.56 | 2.43 |
| Quick Ratio (X) | 5.15 | 17.68 | 2.63 | 1.50 | 2.36 |
| Dividend Payout Ratio (NP) (%) | 20319.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 20319.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -20219.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | -20219.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 56.70 | 1.34 | 1.85 | 1.65 | 0.26 |
| Interest Coverage Ratio (Post Tax) (X) | 39.43 | -1.93 | -1.55 | -0.26 | -1.04 |
| Enterprise Value (Cr.) | 119.90 | -20.82 | 80.00 | 95.58 | 90.44 |
| EV / Net Operating Revenue (X) | 0.00 | -0.35 | 0.93 | 1.11 | 1.31 |
| EV / EBITDA (X) | 207.33 | -3.62 | 7.14 | 8.83 | 47.25 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 1.48 | 1.04 | 1.25 | 1.50 |
| Retention Ratios (%) | -20219.48 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 4.56 | 0.79 | 1.39 | 1.35 | 1.17 |
| Price / Net Operating Revenue (X) | 0.00 | 1.48 | 1.04 | 1.25 | 1.50 |
| EarningsYield | 0.00 | 0.51 | -0.17 | -0.07 | -0.07 |
After reviewing the key financial ratios for Fortis Malar Hospitals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has decreased from 24.18 (Mar 24) to 0.21, marking a decrease of 23.97.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.21. This value is below the healthy minimum of 5. It has decreased from 24.18 (Mar 24) to 0.21, marking a decrease of 23.97.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 3. It has decreased from 29.15 (Mar 24) to 0.20, marking a decrease of 28.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.11. It has decreased from 58.36 (Mar 24) to 16.11, marking a decrease of 42.25.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.11. It has decreased from 58.36 (Mar 24) to 16.11, marking a decrease of 42.25.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.00. It has decreased from 31.46 (Mar 24) to 0.00, marking a decrease of 31.46.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 2. It has decreased from 3.06 (Mar 24) to 0.30, marking a decrease of 2.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has increased from -1.93 (Mar 24) to 0.30, marking an increase of 2.23.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 26.66 (Mar 24) to 0.30, marking a decrease of 26.36.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has decreased from 24.16 (Mar 24) to 0.20, marking a decrease of 23.96.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 2. It has decreased from 24.16 (Mar 24) to 0.20, marking a decrease of 23.96.
- For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. It has decreased from 9.74 (Mar 24) to 0.00, marking a decrease of 9.74.
- For PBIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. It has increased from -6.12 (Mar 24) to 0.00, marking an increase of 6.12.
- For PBT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. It has decreased from 84.74 (Mar 24) to 0.00, marking a decrease of 84.74.
- For Net Profit Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 76.81 (Mar 24) to 0.00, marking a decrease of 76.81.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 8. It has decreased from 76.81 (Mar 24) to 0.00, marking a decrease of 76.81.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.29. This value is below the healthy minimum of 15. It has decreased from 41.40 (Mar 24) to 1.29, marking a decrease of 40.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.91. This value is below the healthy minimum of 10. It has increased from -3.29 (Mar 24) to 1.91, marking an increase of 5.20.
- For Return On Assets (%), as of Mar 25, the value is 1.06. This value is below the healthy minimum of 5. It has decreased from 39.11 (Mar 24) to 1.06, marking a decrease of 38.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.00. It has decreased from 0.46 (Mar 24) to 0.00, marking a decrease of 0.46.
- For Current Ratio (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 3. It has decreased from 17.68 (Mar 24) to 5.15, marking a decrease of 12.53.
- For Quick Ratio (X), as of Mar 25, the value is 5.15. This value exceeds the healthy maximum of 2. It has decreased from 17.68 (Mar 24) to 5.15, marking a decrease of 12.53.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 20,319.48. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 20,319.48, marking an increase of 20,319.48.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20,319.48. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 20,319.48, marking an increase of 20,319.48.
- For Earning Retention Ratio (%), as of Mar 25, the value is -20,219.48. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -20,219.48, marking a decrease of 20,219.48.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is -20,219.48. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -20,219.48, marking a decrease of 20,219.48.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 56.70. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 56.70, marking an increase of 55.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 39.43. This value is within the healthy range. It has increased from -1.93 (Mar 24) to 39.43, marking an increase of 41.36.
- For Enterprise Value (Cr.), as of Mar 25, the value is 119.90. It has increased from -20.82 (Mar 24) to 119.90, marking an increase of 140.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has increased from -0.35 (Mar 24) to 0.00, marking an increase of 0.35.
- For EV / EBITDA (X), as of Mar 25, the value is 207.33. This value exceeds the healthy maximum of 15. It has increased from -3.62 (Mar 24) to 207.33, marking an increase of 210.95.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.00, marking a decrease of 1.48.
- For Retention Ratios (%), as of Mar 25, the value is -20,219.48. This value is below the healthy minimum of 30. It has decreased from 0.00 (Mar 24) to -20,219.48, marking a decrease of 20,219.48.
- For Price / BV (X), as of Mar 25, the value is 4.56. This value exceeds the healthy maximum of 3. It has increased from 0.79 (Mar 24) to 4.56, marking an increase of 3.77.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 1.48 (Mar 24) to 0.00, marking a decrease of 1.48.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.51 (Mar 24) to 0.00, marking a decrease of 0.51.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fortis Malar Hospitals Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.91% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.29% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 39.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.15
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.8 (Industry average Stock P/E: 92.11)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Fortis Hospital, Sector 62, Mohali Punjab 160062 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Daljit Singh | Chairman (Non - Executive) & Non Independent Direc |
| Mr. Chandrasekar Ramasamy | Whole Time Director |
| Ms. Richa Singh Debgupta | Non Exe.Non Ind.Director |
| Ms. Shailaja Chandra | Independent Director |
| Ms. Suvalaxmi Chakraborty | Independent Director |
| Dr. Ritu Garg | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Fortis Malar Hospitals Ltd?
Fortis Malar Hospitals Ltd's intrinsic value (as of 30 December 2025) is 1.99 which is 96.55% lower the current market price of 57.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 108 Cr. market cap, FY2025-2026 high/low of 98.7/55.2, reserves of ₹15.62 Cr, and liabilities of 37.19 Cr.
What is the Market Cap of Fortis Malar Hospitals Ltd?
The Market Cap of Fortis Malar Hospitals Ltd is 108 Cr..
What is the current Stock Price of Fortis Malar Hospitals Ltd as on 30 December 2025?
The current stock price of Fortis Malar Hospitals Ltd as on 30 December 2025 is 57.6.
What is the High / Low of Fortis Malar Hospitals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fortis Malar Hospitals Ltd stocks is 98.7/55.2.
What is the Stock P/E of Fortis Malar Hospitals Ltd?
The Stock P/E of Fortis Malar Hospitals Ltd is 23.8.
What is the Book Value of Fortis Malar Hospitals Ltd?
The Book Value of Fortis Malar Hospitals Ltd is 18.3.
What is the Dividend Yield of Fortis Malar Hospitals Ltd?
The Dividend Yield of Fortis Malar Hospitals Ltd is 0.00 %.
What is the ROCE of Fortis Malar Hospitals Ltd?
The ROCE of Fortis Malar Hospitals Ltd is 0.83 %.
What is the ROE of Fortis Malar Hospitals Ltd?
The ROE of Fortis Malar Hospitals Ltd is 0.56 %.
What is the Face Value of Fortis Malar Hospitals Ltd?
The Face Value of Fortis Malar Hospitals Ltd is 10.0.